# Azacytidine Plus FLAG for Relapsed or Refractory AML

> **NCT02275663** · PHASE2 · UNKNOWN · sponsor: **King Fahad Medical City** · enrollment: 37 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacytidine
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** Filgrastim

## Key facts

- **NCT ID:** NCT02275663
- **Lead sponsor:** King Fahad Medical City
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2017-10
- **Final completion:** 2018-10
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2015-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02275663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02275663, "Azacytidine Plus FLAG for Relapsed or Refractory AML". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02275663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*